Caribou Biosciences, Inc. 8-K

What Happened

• On May 7, 2026, Caribou Biosciences, Inc. (CRBU) filed Form 8-K under Item 2.02 to announce its financial results for the quarter ended March 31, 2026 and to provide a business update. The company furnished a press release as Exhibit 99.1 to the filing. The report was signed by President and CEO Rachel E. Haurwitz, Ph.D.

Key Details

• Filing date: May 7, 2026 (Form 8-K, Item 2.02).
• Reporting period: Quarter ended March 31, 2026 (quarterly results/earnings announced via press release).
• Exhibit included: Press release furnished as Exhibit 99.1 (details of financial results and business update are in that exhibit).
• Authorized signature: Rachel E. Haurwitz, Ph.D., President and Chief Executive Officer.

Why It Matters

• The 8-K signals the company has publicly released its quarterly earnings and business update; investors should review the attached press release (Exhibit 99.1) for specific figures on revenue, expenses, cash position, pipeline progress, or guidance. This filing is a routine but material disclosure of quarterly results and operational developments that can affect CRBU’s stock and investor decisions.